A majority of the job cuts would be in the US, it is learnt.
“Ranbaxy is planning to lay off field force globally… mainly in the US. The company was contemplating this for some time, especially in view of the issues there.
The business has suffered because of regulatory issues through past years. Besides, it also had to incur additional costs to settle those issues,” an industry source told Business Standard.
An email query sent to Ranbaxy did not elicit any response.
According to a company official who did not wish to be named, Ranbaxy’s current global field force stands at around 14,600, of which 5,000-5,200 are in India.
Early last week, Ranbaxy pleaded guilty to making fraudulent statements to the US Food and Drugs Administration (US FDA) about how it tested drugs at two of its Indian plants and agreed to pay $500 million as penalty.
This is the largest false-claims case involving a generics drugs maker in the US.
Ranbaxy, in papers filed in a Federal court in Baltimore, admitted it had sold batches of drugs that were improperly manufactured, stored and tested.
The generic drugs in question had been manufactured at the company’s facilities at Paonta Sahib and
After US, India to probe Ranbaxy's documents
Daiichi pursuing legal action on ex-shareholders
Ranbaxy 'systematically violated' norms: Whistleblower
Markets extend losses, capital goods shares slump
What the Tata Steel write-off REVEALS